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Abstract
Introduction:  Current therapy options for chronic myeloid leukemia (CML) include conventional chemotherapy, allogeneic stem cell
transplant, interferon-alfa, and imatinib mesylate, which has recently achieved gold standard status. Although the majority of patients initially
respond well to treatment with imatinib, wider clinical experience with this drug has resulted in the development of imatinib resistance being
increasingly documented. There is therefore an unmet medical need for novel therapies to override imatinib resistance in CML.
Aims: This review summarizes the emerging evidence for the potential use of dasatinib in the treatment of imatinib-resistant CML.
Disease and treatment: Dasatinib is a novel small molecule that has shown potent antileukemic activity in imatinib-resistant cell lines, malignant
marrow cells isolated from patients with imatinib-resistant CML, and in mouse xenograft models of imatinib-resistant CML. Preliminary data from
an initial phase I dose escalation trial have been encouraging, indicating that dasatinib is generally well tolerated and produces hematologic and
cytogenetic responses in patients with imatinib-resistant CML in all phases of the disease. The maximum tolerated dose (MTD) has not yet been
reached, and dose escalation continues to determine the dose range that yields optimal results.
Profile: Although dasatinib is still in the early stages of development, the potential impact of this molecule on the treatment of CML could
be revolutionary, not only providing a much needed treatment option for patients with imatinib-resistant CML, but also, combined with
imatinib, could possibly prove useful in delaying the onset of resistance to treatment. Furthermore, combined with other agents active in
CML, dasatinib could have potential utility in purging residual leukemic cells in patients whose disease is controlled by imatinib.
Key words: dasatinib, BMS-354825, BCR-ABL, SRC-ABL kinase inhibitor, chronic myeloid leukemia (CML), imatinib resistance, treatment,
evidence, outcomes
Outcome measure Emerging evidence
Hematologic response Achieved in the majority of patients, regardless of stage of disease
Cytogenic response Achieved in substantial numbers of patients, even though the optimal dose has not yet been
determined
Molecular response 1–2 log reduction in BCR-ABL transcripts associated with major cytogenetic responses in patients
with chronic phase CML
Core emerging evidence summary for dasatinib in imatinib-resistant chronic myeloid leukemiaScope, aims, and objectives
Dasatinib (BMS-354825; Bristol-Myers Squibb) is a small molecule
investigational drug, which is currently in phase I development to
override imatinib resistance in chronic myeloid leukemia (CML).
This review summarizes the disease background, current therapy
options, and unmet medical needs, and examines the emerging
evidence for the potential use of dasatinib in the treatment of
imatinib-resistant CML. 
Methods
The English language medical literature was searched on February 8,
2005 in the following databases:
• PubMed, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi
• EMBASE, http://www.datastarweb.com
• Database of Abstracts of Reviews of Effectiveness (DARE), NHS
Economic Evaluations Database (NHSEED), Health Technology
Assessment (HTA), http://www.york.ac.uk/inst/crd/darehp.htm
(all fields searched in all three databases together)
• NHS HTA, http://www.ncchta.org
• National Guideline Clearing House, http://wwwguideline.gov
• Cochrane Database of Systematic Reviews (CDSR),
http://cochrane.org/index0.htm
• Clinical Evidence (BMJ), http://www.clinicalevidence.com
• EBM reviews (ACP Journal Club), http://www.acpjc.org. 
The search terms used were “BMS-354825” OR “BMS354825”,
and the cut-off dates were from the beginning of the database to
the date of the search. 
A total of six articles were identified: three preclinical articles, and
three editorial/opinion articles. No relevant systematic reviews or
treatment guidelines involving dasatinib were identified. 
The proceedings of the following oncology society meetings were
also searched for relevant abstracts, again using the search terms
“BMS-354825” OR “BMS354825”:
• American Society of Hematology (ASH) 2004
• American Society for Clinical Oncology (ASCO) 2004 and 2005
• American Association for Cancer Research (AACR) 2004
• European Society for Medical Oncology (ESMO) 2004
• European Hematology Association (EHA) 2004. 
A total of 23 abstracts was identified, seven of which were
disregarded on the basis of not concerning dasatinib (n=1) or not
being relevant to the treatment of CML (n=6). Among the relevant
abstracts, nine reported on the outcomes of preclinical studies, and
seven on preliminary clinical data (Table 1).
Disease overview
CML, also known as chronic myelogenous leukemia, is a clonal
myeloproliferative disorder that originates from a single abnormal
hematopoietic stem cell (Faderl et al. 1999; John et al. 2004; Stone
2004). Myeloid progenitors expand at various stages of maturation
and are released prematurely from the bone marrow into the
peripheral blood, subsequently infiltrating extramedullary sites,
particularly the spleen. In the advanced stages of the disease
(accelerated phase or blast crisis) the liver and lymph nodes may
also become involved. 
Epidemiology
CML accounts for around 15% of all adult leukemias and is slightly
more common in males than females (ratio 1.3:1). The incidence of
CML is estimated at 1–2 new cases per 100 000 per annum
(Maness & McSweeney 2004), and increases with advancing age
(Fig. 1). The median age at CML diagnosis is 45–55 years, although
12–30% of patients present after the age of 60 years, and 10%
present before their 20th birthday (Cortes et al. 1996, 1997; Faderl
et al. 1999; Hill & Meehan 1999; Jemal et al. 2002; Besa 2004).
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Fig. 1 | Age-specific incidence rate of chronic myeloid leukemia
(CML) (1995–1998) increases with age. National Cancer Institute
Surveillance Epidemiology and End Results (SEER) data (Table
XIII-6, chronic myeloid leukemia), which is publicly available at
http://seer.cancer.gov/csr/1973_1999/leukemia.pdf; graph
adapted from the Leukemia and Lymphoma Society website:
http://www.leukemia-lymphoma.org/all_mat_detail.adp?item_
id=2119&sort_order=48cat_id=1209
Number of records
Category Full papers Abstracts
Initial search 6 23
records excluded 0 7
records included 6 16
Table 1 | Evidence base included in the review (preclinical and
phase I only)3
Molecular basis of CML
At the molecular level CML is caused by the constitutive expression
of the bcr-abl oncogene which is created by a balanced reciprocal
translocation between chromosomes 9q and 22q (Fig. 2) (Nowell &
Hungerford 1960; Rowley 1973; Faderl et al. 1999). This
translocation, known as the Philadelphia translocation, results in the
joining of the 3' segment of the abl (Ableson leukemia virus) gene on
9q34 and the 5' segment of the bcr (breakpoint cluster region) gene
on 22q11, to form the bcr-abl hybrid fusion gene carried on a
shortened chromosome 22. This shortened chromosome 22, known
as the Philadelphia chromosome (Ph+), is the hallmark of CML. 
The BCR-ABL oncoprotein is a deregulated nonreceptor tyrosine
kinase with increased activity compared with the ‘wild-type’ ABL
kinase. Constitutive expression of BCR-ABL leads to malignant
transformation by interfering with the signal transduction pathways
involved in the control of apoptosis, cellular proliferation, and
adherence of CML progenitors to bone marrow stromal elements
(Goldman 1997; Faderl et al. 1999; John et al. 2004). 
In 50–80% of CML cases, disease progression is associated with
the acquisition of additional cytogenetic and molecular genetic
changes, which often precede hematologic and clinical
manifestations. Minor cytogenetic changes include monosomies of
chromosomes 7 and 17 (one chromosome missing), trisomies of
chromosomes 17 and 21 (an extra chromosome), and a
translocation between chromosomes 3 and 12 [t(3;12)(q26,q22)]
(Mitelman 1993). Major cytogenetic changes include trisomy 8,
isochromosome 17q, trisomy 19, and an additional Philadelphia
chromosome (disomy Ph+) (Kantarjian et al. 1987; Derderian et al.
1993; Mitelman 1993). The most frequent molecular abnormalities
are alterations to the tumor suppressor, p53 (Ahuja et al. 1989). 
Signs and symptoms
The onset of CML is associated with signs and symptoms that usually
develop gradually. Most patients experience fatigue and reduced
exercise tolerance due to anemia. Discomfort on the left side of the
abdomen is also a frequent complaint as a result of splenomegaly. In
addition, patients with CML often develop a hypermetabolic state,
which is associated with fever, excessive sweating, and weight loss
(Faderl et al. 1999; Hill & Meehan 1999; Besa 2004). 
Disease staging
CML follows a triphasic clinical course (Fig. 3). Initially there is the
chronic phase, in which the disease is often indolent, followed by
the accelerated phase, and subsequent progression to the terminal
phase, known as blast crisis (Faderl et al. 1999; Hill & Meehan
1999; Maness & McSweeney 2004). 
Chronic phase
The chronic phase is characterized by <5% blasts (immature
myeloid leukemic cells) in the blood and bone marrow; no
malignant cells outside of the blood, bone marrow, or spleen;
and absent/mild symptoms of CML. Most patients (~80%) are in
the chronic phase at diagnosis. The median duration of the
chronic phase is 3–5 years, before progression to the
accelerated phase. 
Accelerated phase
The accelerated phase is defined by the presence of one or more
of the following: persistent presence of 10–30% blasts in the blood
and bone marrow; white blood cell count >50 000/µL with an
increase or decrease in platelets and low red blood cell count
despite treatment; progressive splenomegaly; involvement of
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Fig. 2 | The Philadelphia translocation: a
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Fig. 3 | Chronic myeloid leukemia: triphasic clinical courseorgans other than the bone marrow or spleen; acquired cytogenetic
abnormalities additional to the Philadelphia chromosome; and
persistent, unexplained fever or bone pain. The accelerated phase
of CML is generally short-lived, with progression to blast crisis
within a median of 6–9 months.
Blast crisis
The final stage of CML, blast crisis, is defined by the presence of
>30% blasts in the blood and bone marrow. These immature
leukemic blasts may form tumor masses in the bone or lymph
nodes. At this stage, the disease is considered to have
progressed to an aggressive, acute form of leukemia that is
rapidly fatal, with a median survival of 3–6 months. In one-third of
cases, the blasts develop a lymphoid morphology and begin to
express lymphoid markers, whereas in the remaining two-thirds
the blasts have a phenotype similar to that of acute myeloblastic
leukemia (Griffin et al. 1983). It is important to distinguish between
these two groups of patients because those whose leukemia is in
lymphoid blast crisis (Ph+ ALL) can respond to treatment with
regimens that are active against acute lymphoid leukemia
(Derderian et al. 1993), whereas patients with myeloid
morphology do not. 
Diagnosis
Approximately 50% of patients with CML are asymptomatic at
diagnosis; their disease being discovered after routine blood films
show leukocytosis. Initial evaluations typically involve a physical
examination and morphologic review and immunotyping of the
blood, bone marrow, and, where appropriate, a lymph node or
spleen biopsy. However, a confirmed diagnosis of CML depends on
demonstrating the presence of the Ph+ chromosome
cytogenetically in the bone marrow (detected in 95% of patients),
or detecting the presence of the bcr-abl oncogene by polymerase
chain reaction (PCR), fluorescent in situ hybridization (FISH), or
Southern analysis; detecting the BCR-ABL transcript by RT-PCR or
Northern analysis; or demonstrating the presence of the BCR-ABL
oncoprotein by Western analysis (Faderl et al. 1999; Hill & Meehan
1999; Vardiman et al. 2001). 
Evaluation of response 
Response to therapy for CML can be evaluated on three levels. In
increasing order of remission depth these are hematologic responses,
cytogenetic responses, and molecular responses. 
A complete hematologic response refers to normalization of blood
counts lasting for at least 4 weeks. However, patients who achieve
complete hematologic responses may still have detectable levels
of Ph+ cells. A complete cytogenetic response refers to the
absence of Ph+ cells on cytogenetic analysis. For patients who
achieve complete cytogenetic responses, a more sensitive
measurement of residual disease may be conducted using BCR-
ABL transcripts, detected by reverse transcriptase PCR (RT-PCR),
as a marker for residual disease. Elimination of residual disease to
levels below the limit of detection by RT-PCR is known as a
complete molecular remission. Incomplete cytogenetic responses
are referred to as major or minor responses according to the
percentages of Ph+ cells detected. 
Goals of therapy
The goal of therapy usually depends upon disease phase. For
patients with chronic phase CML the principal goal of therapy has
been to attain a complete cytogenetic response, as this has
consistently been correlated with prolonged survival (Kantarjian et al.
1995, 2004; Clift & Storb 1996; Guilhot et al. 1997; ICSGCML 1998;
Clift et al. 1999; Stone 2004). However, molecular responses are
likely to become the new goal of therapy for these patients, with the
aim of further improving response duration and overall survival. Other
important objectives of therapy for patients in the chronic phase
include normalizing blood counts (complete hematologic responses),
controlling the signs and symptoms of CML, and delaying disease
progression to the accelerated phase or blast crisis. 
In contrast, for patients in the accelerated phase or blast crisis, the
primary goal of therapy is often to reestablish the chronic phase.
Regardless of therapy the prognosis for patients with accelerated or
blast phase CML is currently poor (Shah et al. 2004a; Travis 2004).
Current therapy options
Considerable advances have been made in the treatment of CML
since the first patients were treated with Fowler’s solution in the
1860s (Fig. 4). 
Chemotherapy 
Busulfan, an alkylating agent introduced in the 1950s, reduces
white blood cell counts and disease-related signs and symptoms,
but does not produce a complete cytogenetic response, or
significantly delay disease progression. In addition, busulfan is
poorly tolerated and is associated with serious adverse events,
such as myelosuppression and pulmonary/hepatic/cardiac fibrosis
(Hehlmann et al. 1993).
Treatment with hydroxyurea, a ribonucleotide reductase inhibitor,
can achieve hematologic remissions and reduce splenomegaly, and
offers a survival advantage over busulfan. Hydroxyurea is also
better tolerated than busulfan, particularly with regard to bone
marrow recovery. However, like busulfan, hydroxyurea produces
neither a complete cytogenetic remission, nor a significant delay in
disease progression to the accelerated phase or blast crisis
(Hehlmann et al. 1993).
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Fig. 4 | Advances in the treatment of chronic myeloid leukemia: an
historical perspective. allo-SCT, allogeneic stem cell transplant;
BU, busulfan; HU, hydroxyurea; IFN-α, interferon-alfa; MUD,
matched unrelated donor
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The investigational drug, homoharringtonine, a plant alkaloid
protein synthesis inhibitor, is also active in CML as monotherapy
and in combination with cytarabine (Kantarjian et al. 2000, 2001). In
patients with late chronic phase CML (diagnosed for >12 months)
treatment with homoharringtonine produced complete hematologic
and cytogenetic responses in 72 and 31%, respectively (O’Brien et
al. 1995). However, high doses and short infusion schedules of
homoharringtonine are associated with serious cardiovascular
complications, including hypotension and cardiac arrhythmias
(Kantarjian et al. 2000, 2001). Consequently homoharringtonine has
not received approval for the treatment of CML. 
Allogeneic stem cell transplantation
Allogeneic hematopoietic stem cell transplantation (allo-SCT) is
currently the only treatment with long-term data demonstrating
curative potential in CML (Stone 2004). This is due to the graft-
versus-leukemia (GVL) effect, an immunotherapeutic phenomenon
in which allogeneic T and NK cells recognize and destroy tumor
cells (Bleakley & Riddell 2004). 
Up to 70% of patients with early chronic phase CML are cured
following allo-SCT (Stone 2004). However, the probability of long-
term survival is substantially reduced in patients who are
transplanted in the accelerated or blast phases of the disease (Clift
& Storb 1996; Horowitz et al. 1996), and progressively worsens with
advancing age (Clift & Storb 1996; Gratwohl & Hermans 1996;
Gratwohl et al. 1998). Furthermore, allo-SCT procedures are
associated with significant morbidity [graft-versus-host disease
(GVHD) and infections], and high rates of treatment-related
mortality (20–40%) (Silver et al. 1999). An HLA-matched, related
donor is optimal, but is available for <30% of patients (Clift & Storb
1996; Horowitz et al. 1996). In the absence of an HLA-matched,
related donor, an HLA-matched, unrelated donor transplant may be
considered, but is usually associated with increased morbidity
(GVHD and infections, including cytomegalovirus reactivation) and
an increased risk of treatment-related mortality, compared with an
HLA-matched, related donor transplant (Hansen et al. 1998;
Weisdorf et al. 2002). 
Considering the current evidence, the best candidates for allo-SCT
would therefore appear to be young patients with recently
diagnosed, early-stage disease for whom matched, related donors
are available. Consequently, <40% of patients with CML are eligible
for allo-SCT procedures, despite its curative potential. However,
recently developed reduced-intensity conditioning regimens for
allo-SCT have been associated with reduced morbidity and
mortality risks, and are likely to extend this potentially curative
procedure to patients previously considered ineligible because of
age and/or advanced disease (i.e. CML in the accelerated phase or
blast crisis) (Or et al. 2003).
Interferon
The mechanism of action of interferon-alfa (IFN-alfa) is poorly
understood. For patients with chronic phase CML, IFN-alfa produces
complete cytogenetic responses in 8–38% of patients (ICSGCML
1998), and significantly prolongs survival compared with hydroxyurea
or busulfan (Hehlmann et al. 1994; ICSGCML 1994). Furthermore,
patients who achieve major cytogenetic responses following
treatment with IFN-alfa survive longer, compared with those who fail
to achieve a major cytogenetic response (Kantarjian et al. 1995). In
common with other treatments for CML, IFN-alfa is most effective in
the chronic phase of the disease (Kantarjian et al. 1998).
In a randomized study comparing the safety and efficacy of IFN-
alfa + cytarabine vs IFN-alfa monotherapy in patients with chronic
phase CML, the addition of cytarabine was associated with
significantly higher complete hematologic response rates (66 vs
55%), major cytogenetic response rates (41 vs 24%), and
significantly longer survival (3-year survival rates: 85.7 vs 79.1%)
(Guilhot et al. 1997). 
In a long-term follow-up of 512 patients with CML treated with
IFN-alfa + cytarabine between 1981 and 1995, 27% achieved
complete cytogenetic remissions, and among those patients
achieving complete cytogenetic remissions, 78% achieved 10-year
survival. This confirms the importance of complete cytogenetic
remission as a therapeutic goal in CML (Kantarjian et al. 1995). 
The major drawback of IFN-based therapy is its poor tolerability profile:
10–25% of patients discontinue treatment due to flu-like syndrome,
anorexia, and depression (ICSGCML 1994; Guilhot et al. 1997).
However, despite its poor tolerability profile, IFN-alfa + cytarabine was
the standard of care for many years before the introduction of
imatinib mesylate, and is still used today. 
Imatinib mesylate 
The BCR-ABL oncoprotein is the most directly relevant
therapeutic target in CML. Imatinib mesylate, a small molecule
developed specifically to inhibit BCR-ABL kinase activity, has
revolutionized the treatment of CML, and is currently the gold
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Phase of disease
Chronic
(Kantarjian et al. 2002)
Accelerated
(Talpaz et al. 2002)
Blast crisis
(Sawyers et al. 2002)
Response 400 mg/day 400 mg/day 600 mg/day 400 mg/day 600 mg/day
Complete hematologic 95% 27% 37% 0% 9%
Complete cytogenetic 41% 11% 19% 3% 8%
Major cytogenetic 60% 16% 28% 6% 18%
Minor cytogenetic 5% 8% 6% 3% 2%
Table 2 | Imatinib: phase II responses in treatment of chronic myeloid leukemia
 standard treatment for all phases of CML (Druker et al. 1996,
2001a,b; Peggs & Mackinnon 2003). Phase II studies confirmed
the ability of imatinib to produce both complete hematologic and
cytogenetic remissions in patients in all phases of CML
(Kantarjian et al. 2002; Sawyers et al. 2002; Talpaz et al. 2002). As
expected, outcomes were best among patients with chronic
phase CML, compared with patients with more advanced disease
(see Table 2). In addition, a randomized phase III trial (IRIS)
comparing the safety and efficacy of imatinib vs IFN-alfa +
cytarabine in 1106 patients with newly diagnosed CML
demonstrated that not only was imatinib much better tolerated
than IFN-alfa + cytarabine, it was also significantly more effective
than IFN-alfa + cytarabine with regard to complete hematologic
response rates (O’Brien et al. 2003), complete cytogenetic
response rates (O’Brien et al. 2003), molecular responses
(Hughes et al. 2003), and overall survival (Anstrom et al. 2004)
(summarized in Table 3). Furthermore, baseline quality of life was
maintained among patients treated with imatinib, whilst quality of
life markedly deteriorated among patients treated with INF-alfa +
cytarabine (P=0.001, Hahn et al. 2003).
The efficacy of high-dose imatinib therapy in chronic phase CML
has recently been investigated. The outcomes of these studies
are summarized in Table 4. A small single-arm study conducted in
patients with chronic phase CML who had failed treatment with
IFN-alfa suggested that high-dose imatinib (400 mg twice a day)
improved cytogenetic and molecular response rates without
increasing toxicity, compared with responses typically achieved
with standard-dose imatinib (400 mg once a day) (Cortes et al.
2003). These findings were subsequently confirmed in an
independent study conducted in patients with newly diagnosed
CML (Kantarjian et al. 2004). Dose escalation of imatinib to
600 mg once a day or 400 mg twice a day also appears to be
effective in overcoming disease relapse/refractoriness in patients
who have failed treatment with standard-dose imatinib (Kantarjian
et al. 2003). 
Imatinib has generally been well tolerated, even in high-dose trials.
The majority of adverse events were of mild-to-moderate severity,
and the most frequently reported adverse events were edema,
nausea, diarrhea, muscle cramps, and rash. However,
myelosuppression was more frequent in patients with accelerated
phase or blast crisis CML and in patients treated with high-dose
imatinib regimens.
In summary, extensive experience with imatinib in clinical trials has
shown this agent to be highly effective and well tolerated in the
treatment of CML. In common with other treatments for CML, best
responses are achieved in patients with chronic phase disease; up
to 90% of patients achieve complete cytogenetic remissions
following treatment with high-dose imatinib, and up to 41% achieve
molecular remissions in which BCR-ABL transcripts are
undetectable by RT-PCR. 
Treatment guidelines
Although guidelines for the treatment of CML are available (ASH
1999), these are out of date as they do not take into account the
advances in treatment achieved with imatinib. Since the
establishment of imatinib as first-line treatment for CML, one of the
key dilemmas facing healthcare providers is how best to
incorporate it into the treatment of patients who are candidates for
potentially curative (but toxic) allo-SCT procedures (Deininger et al.
2003; Peggs & Mackinnon 2003). Consequently, ASH is planning to
update its existing guidelines in the near future (ASH online,
accessed February 14, 2005). 
Cost of care
Although several studies have investigated the cost-effectiveness
of individual treatment strategies in specific patient subgroups
(Kattan et al. 1996; Lee et al. 1998; Beck et al. 2001; Dalziel et al.
2004; Reed et al. 2004; Warren et al. 2004), few data are available
regarding the overall economic and societal costs of CML.
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Category Imatinib IFN-alfa/
cytarabine
P
Complete hematologic response 95.5% 55.5% <0.001
Complete cytogenetic response 73.8% 8.5% <0.001
Molecular responses (3-log
reduction in BCR-ABL
transcripts at 12 months)
39% 2% <0.001
Survival 6.2-year survival advantage with
imatinib over IFN-alfa/cytarabine
IFN-alfa, interferon-alfa.
Table 3 | IRIS trial: phase III responses
Table 4 | High-dose imatinib in patients with chronic myeloid leukemia in chronic phase
Patient group Responses
Hematologic Cytogenetic Molecular
Failed treatment with interferon-alfa 100% (complete) 89% (complete) 56% (BCR-ABL transcripts
undetectable in 41%)
Newly diagnosed Not reported 90% (complete) 63% (BCR-ABL transcripts
undetectable in 28%)
Hematologic resistance/relapse with standard dose imatinib 45% (complete)
20% (partial)
10% (partial) Not reported
Cytogenetic resistance/relapse with standard dose imatinib 56% (complete or partial) Not reported7
Unmet needs
Although most CML patients respond well to initial treatment with
imatinib, resistance is a major problem. Indeed, a minority of
previously untreated patients are resistant to imatinib from the outset
(innate resistance), and the majority of those who initially respond to
imatinib subsequently develop resistance (acquired resistance).
Treatment options for patients with imatinib-resistant CML are
limited to allo-SCT, assuming the patient is eligible and a suitable
donor is available, or investigational therapies, such as
farnesyltransferase inhibitors (Hoover et al. 2002) or arsenic trioxide
(La Rosee et al. 2002). Furthermore, the onset of imatinib resistance
appears to correlate with disease progression and worsening
prognosis (Shah et al. 2002). Therefore there is a need for novel
agents to override imatinib resistance in CML.
An agent that produces complete cytogenetic and molecular
responses, delays disease progression, and significantly improves
survival expectation in imatinib-resistant CML patients would
represent a major advance in the treatment of CML. 
To develop new strategies to overcome imatinib resistance it is
necessary to understand the underlying resistance mechanisms.
Clinical resistance is primarily mediated by the acquisition of
mutations within the BCR-ABL oncoprotein that prevent imatinib
binding, and to a lesser extent by bcr-abl gene amplification. Other
mechanisms of resistance that have been suggested include
elevated levels of multidrug resistance protein, and overexpression
of SRC kinases (Mahon et al. 2000; Nardi et al. 2004; Stone 2004).
The activation loop of ABL kinase oscillates between open (active)
and closed (inactive) conformations. Imatinib can only bind when the
activation loop is in the closed (inactive) conformation, locking the
kinase in the inactive state (Schindler et al. 2000). At least 17 different
amino acid substitutions within BCR-ABL have been identified that
cause imatinib resistance by preventing imatinib binding (Hochhaus et
al. 2002; Roche-Lestienne et al. 2002; Shah et al. 2002; von Bubnoff
et al. 2002; Al-Ali et al. 2004). Some of these mutations directly affect
the imatinib binding site. However, the majority of imatinib-resistance
mutations occur in the activation loop, locking it into the open (active)
conformation, which precludes imatinib binding.
Structural studies have demonstrated that pyriodol[2,3-D]pyrimidine
dual SRC-ABL kinase inhibitors bind to BCR-ABL, inhibiting its
kinase activity, regardless of whether the activation loop is in the
open (active) or closed (inactive) conformation (Nagar et al. 2002). In
principle, the dual SRC-ABL inhibitors, which have less stringent
binding requirements than imatinib, could potentially override
imatinib resistance due to their ability to bind to and inhibit ABL
kinase when the activation loop is in the open (active) conformation.
The potential utility of dual SRC-ABL inhibitors to override imatinib
resistance in CML is further supported by recent data indicating
that imatinib resistance is associated with upregulated expression
of the SRC kinase, Lyn (Donato et al. 2004; Wu et al. 2004).
Drug review
Dasatinib is a dual function SRC-ABL kinase inhibitor currently
being developed for the treatment of patients with imatinib-
resistant CML. The discovery of dasatinib is discussed in a recent
review (Lombardo et al. 2004).
Preclinical evidence 
X-ray crystallography 
X-ray crystallography has confirmed that, like imatinib, dasatinib
binds to the adenosine triphosphate binding site of ABL kinase with
the central cores of the two drugs occupying overlapping regions,
but extending in opposite directions. This study confirmed the
ability of dasatinib to bind to ABL kinase when the activation loop
is in the open (active) conformation, thus confirming the theoretical
potential for dasatinib to override imatinib resistance. Furthermore,
there were no apparent steric clashes to preclude dasatinib from
binding when the activation loop is in the closed (inactive)
conformation (Tokarski et al. 2004). This apparent ability of
dasatinib to bind to ABL kinase in multiple conformational states
indicates that it may have the potential for greater potency
compared with imatinib. 
Evidence for in vitro activity against imatinib-resistant
BCR-ABL isoforms
In vitro cell-based assays have demonstrated that dasatinib is more
potent (×2-log) than imatinib in inhibiting unmutated BCR-ABL
activity (Shah et al. 2004a). This increased potency may be due to
the apparent ability of dasatinib to bind to ABL kinase in multiple
conformational states (Tokarski et al. 2004). 
Dasatinib has also shown in vitro activity against 14 of 15 imatinib-
resistant cell lines expressing mutant BCR-ABL isoforms,
demonstrated by inhibition of kinase activity, and inhibition of cell
growth (Shah et al. 2004a). The one imatinib-resistant cell line that
was also resistant to dasatinib carried the T315I mutation,
suggesting that this mutation confers cross resistance to both
imatinib and dasatinib. The sensitivity of the different imatinib-
resistance mutations to treatment with dasatinib was varied. This
suggests that, in the future, individual patient’s BCR-ABL mutation
status may guide decision making regarding the minimum serum
concentrations of dasatinib required for therapeutic benefit. 
In addition to the apparent ability of dasatinib to override imatinib
resistance caused by mutations in BCR-ABL, recent in vitro data
suggest that, like imatinib, dasatinib is selective for leukemic vs
normal hematopoietic stem cells. Dasatinib (5nM) did not inhibit
growth of bone marrow progenitors isolated from healthy volunteers,
but did result in 60–80% growth inhibition in bone marrow
progenitors isolated from CML patients with unmutated BCR-ABL or
M351T imatinib-resistant BCR-ABL (Shah et al. 2004a). 
A battery of pharmacogenomic biomarkers (other than BCR-ABL
mutations) have also been identified, which predict sensitivity to
dasatinib in tumor cell lines (Clark et al. 2005).
Evidence of antileukemic activity in mouse models of
imatinib-sensitive and imatinib-resistant CML
Models of BCR-ABL-dependent disease have been produced by
injecting mice with cell lines that express unmutated BCR-ABL, or
imatinib-resistant BCR-ABL isoforms (Shah et al. 2004a,b).
Following administration of dasatinib (10 or 15 mg/kg),
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up to 7 h, returning to baseline after 12 h. Based on these
preliminary data, a dose of 10 mg/kg was chosen for evaluation of
dasatinib efficacy. 
Three days after injecting the cell lines, mice were treated with
vehicle or dasatinib for 2 weeks. All vehicle-treated mice developed
progressive disease, with massive hepatic and splenic infiltration,
which resulted in death in around 15 days. Conversely, dasatinib-
treated mice with unmutated BCR-ABL tumors or M351T (imatinib-
resistant) tumors appeared to be healthy (no weight loss, lethargy,
or ruffled fur), and showed a >1-log decrease in BCR-ABL kinase
activity (measured by bioluminescence assay), normal spleen
weight, and significantly longer survival compared with vehicle-
treated animals. Consistent with in vitro studies, mice with T315I
BCR-ABL tumors did not respond to treatment with dasatinib (no
significant reduction in kinase activity by bioluminescence assay)
and showed no significant improvement in survival compared with
vehicle-treated animals. 
Treatment with dasatinib at doses as low as 5 mg/kg per day has
been shown to be curative in other murine xenograft models of
imatinib-resistant CML (Lee et al. 2004). 
Evidence for antileukemic activity in a mouse model of
intracranial CML
Growing evidence suggests that imatinib is a poor penetrator of the
blood–brain barrier, resulting in subtherapeutic levels of the drug in
the central nervous system. Several clinical cases have been
reported in which central nervous system relapse has occurred
despite complete hematologic responses in the blood and bone
marrow (Leis et al. 2004). Furthermore, in at least one animal model
of CML, imatinib has shown limited ability to cross the blood–brain
barrier, allowing the central nervous system to act as a sanctuary
for leukemic cells (Wild et al. 2004). 
It has been suggested that the limited ability of imatinib to cross the
blood–brain barrier may be due to the fact that it is a substrate for
P-glycoprotein. In contrast, dasatinib is not a P-glycoprotein
substrate, and is therefore more likely to achieve therapeutic levels
in the central nervous system. To test this hypothesis a mouse
model of intracranial CML was created by transplanting K562 CML
tumors intracranially. Mice were treated with dasatinib twice daily
for up to 40 days. Tumor regression was achieved at a dasatinib
dose of 15 mg/kg, with complete stasis of intracranial tumor growth
during therapy. In addition, survival was increased by 450 and
268% at dose levels of 15 and 5 mg/kg, respectively. These
preliminary data indicate that dasatinib may potentially offer
advantages over imatinib in the management of intracranial CML
(Wild et al. 2004). 
Pharmacokinetic profile in mice 
In a model of BCR-ABL-dependent disease, oral dasatinib was
curative over a range of doses (1.25–50 mg/kg). At the minimum
effective dose of 1.25 mg/kg, maximum inhibition of BCR-ABL
activity was observed 3 h after dosing, with complete recovery of
BCR-ABL activity in 7–17 h. This model predicted that a minimum
plasma concentration of 20 nM is required to effectively inhibit
BCR-ABL activity. In addition, while a 1.25 mg/kg per day dose was
curative with twice-daily dosing, a higher 5 mg/kg per day dose
was required for equivalent efficacy with once-daily dosing,
suggesting that twice-daily dosing regimens may be more effective
than once daily (Luo et al. 2004). 
Clinical evidence
Patients with CML who are resistant or intolerant to previous
treatment with imatinib were enrolled onto a phase I dose escalation
study (Fig. 5). This study included 36 patients with chronic phase
CML, eight patients with accelerated phase CML, 18 patients in
blast crisis, and three patients with Ph+ ALL. Patients with chronic
phase CML were treated with dasatinib at doses of 15–180 mg/day
(as a single dose or split into two equal doses) for 5–7 days/week,
whilst patients in the accelerated phase or blast crisis were treated
with dasatinib at doses of 35–90 mg/day twice daily. Responses
according to phase of disease are summarized below.
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Daily dasatinib
dose
Hematologic
responses
Cytogenetic
responses
Response
duration
aCML in blast crisis where blasts have developed lymphoid morphology.
15–180 mg
31 complete (86%)
5 complete
4 major
(31% complete or major)
(29 patients evaluated)
33/36 patients remain
on study for 1+ to 13+
months
6 complete or partial
(75%)
1 minor response
13 complete or partial
(76%)
(17 patients evaluated)
Major response in 53%
35–90 mg
Responses durable for 2+ to 6+ months in 19 patients
2 complete or partial
(100%)
(2 patients evaluated)
Chronic phase
n=36
(31 resistant, 5 intolerant)
Talpaz et al. 2005
Sawyers et al. 2004
Accelerated phase
n=8
Sawyers et al. 2005
Talpaz et al. 2004
Blast crisis
n=18
Sawyers et al. 2005
Talpaz et al. 2004
Ph+ ALLa
n=3
Sawyers et al. 2005
Patients with CML who are 
either resistant or intolerant to treatment with imatinib
Fig. 5 | Phase I responses following
treatment with dasatinib in patients with
Ph+, imatinib-resistant/intolerant chronic
myeloid leukemia (CML)9
Phase I responses: patients with chronic phase CML
To date 36 patients with chronic phase CML enrolled onto this
phase I study (imatinib resistant n=31, imatinib intolerant n=5, BCR-
ABL mutations associated with imatinib resistance n=27) have
been followed for >4 weeks and were evaluable for response
(Sawyers et al. 2004; Talpaz et al. 2005). 
Thirty-one patients (86%) achieved a complete hematologic
response. Only two patients experienced disease progression: one
of whom carried the imatinib resistance mutation, T315I, which was
also associated with resistance to dasatinib in preclinical studies.
Twenty-nine patients were evaluated cytogenetically: 13
demonstrated cytogenetic improvement, including five complete and
four major cytogenetic responses. Hematologic and cytogenetic
responses were achieved in patients with or without BCR-ABL
mutations (Sawyers et al. 2004; Talpaz et al. 2005; Shah et al. 2005).
Furthermore, these responses were durable with 33 of 36 patients
remaining on study for 1+ to 13+ months (Talpaz et al. 2005).
BCR-ABL transcripts were monitored by quantitative RT-PCR in a
subset of 13 patients treated with dasatinib (Shah et al. 2004c).
Four patients (three imatinib resistant, two of whom carried the
known imatinib-resistance mutation, M351T) achieved a major
cytogenetic response, which corresponded with 1- or 2-log
reductions in BCR-ABL transcript levels, and an overall 32%
median reduction in BCR-ABL transcripts after 4 weeks of
treatment. In contrast, none of the nine patients who failed to
achieve a major cytogenetic response achieved a 1-log reduction in
BCR-ABL transcript levels. 
These preliminary data therefore indicate that the achievement of a
major cytogenetic response is associated with 1- or 2-log reduction
in BCR-ABL transcript expression. In addition, quantitative RT-PCR
appears to offer a rapid and reliable method of monitoring disease
burden and response to therapy in this setting (Shah et al. 2004c).
It is worthy of note that similar reductions in BCR-ABL transcript
levels have previously correlated with cytogenetic responses
achieved with imatinib (Shah et al. 2004c). 
Responses in patients with accelerated phase CML,
blast crisis, or Ph+ ALL
To date, 29 patients with accelerated phase CML (n=8), blast crisis
(n=18), or Ph+ ALL (n=3) who entered this phase I trial have
received treatment with dasatinib (Talpaz et al. 2004; Sawyers et
al. 2005). Of 28 patients for whom BCR-ABL mutation status was
known, 16 had mutations known to confer imatinib resistance.
Hematologic response rates (complete and partial) were as
follows: 75% (six of eight) in patients with accelerated phase CML,
76% (13 of 17) in patients in blast crisis, and 100% (two of two) in
patients whose disease had transformed to Ph+ ALL. These
responses were durable for 2+ to 6+ months in 19 patients
(Sawyers et al. 2005).
Among patients in blast crisis, 53% achieved a major cytogenetic
response. Of note, the T315I mutation, which conferred cross
resistance to both imatinib and dasatinib in preclinical models,
was identified in four of six patients who were resistant to
dasatinib therapy.
Safety and tolerability
Dasatinib treatment was generally well tolerated regardless of
disease phase. In patients with chronic phase CML, three of 36
developed grade 4 thrombocytopenia and two of 36 developed
grade 4 neutropenia, all of which were reversible and easily managed
with dose modification. One patient developed a duodenal ulcer, and
mild QTc prolongation was noted (Talpaz et al. 2005). In patients with
advanced disease, eight of 29 developed grade 4 thrombocytopenia,
one patient developed grade 3/4 fluid retention, and two patients
developed tumor lysis syndrome (Sawyers et al. 2005). 
SRC inhibitors are known to be important modulators of T-cell
activation. It is therefore noteworthy that a recent report indicated
that dasatinib induces complete hematologic remission without
affecting the ability of CD8+ and CD4+ T cells to produce Th1 and
Th2 cytokines when stimulated (Gao et al. 2005).
Overall, these preliminary phase I data indicate that dasatinib is
frequently able to override imatinib resistance in patients with
chronic phase disease and those with more advanced disease
(accelerated phase or blast crisis). The drug also appears to be well
tolerated, regardless of the disease phase. The maximum tolerated
dose has yet to be established and dose escalation continues to
establish the dose range that yields optimal results. 
Based on these encouraging data, phase II studies of dasatinib in
the treatment of patients with imatinib-resistant CML are planned. 
Resource utilization
Dasatinib is still in the preliminary stages of clinical development,
and its future use in the treatment of CML will depend upon the
outcomes of phase II and III trials. However, the available preliminary
data suggest that it may potentially provide a much needed
therapeutic option for patients with imatinib-resistant CML. The
future use of dasatinib in the treatment of CML is likely to depend on
its safety profile. In particular, SRC kinase inhibition is associated
with immunosuppression, which raises the possibility that treatment
with dasatinib might be associated with more adverse events than
imatinib (Doggrell 2005). Long-term follow-up data will therefore be
required to fully assess the safety profile of dasatinib. 
In a screen for BCR-ABL mutations conferring resistance to
imatinib and dasatinib, the mutation profiles conferring resistance
to the two drugs were different and 30–50-fold fewer mutant clones
were resistant to both imatinib and dasatinib, compared with each
drug individually (Burgess et al. 2004). This suggests that dasatinib
in combination with imatinib could potentially be useful in the first-
line management of CML, particularly with regard to delaying the
development of drug resistance.
In addition, given the apparent potency of dasatinib, its use in
combination with other agents known to be active in CML could
potentially be an effective strategy for purging residual disease and
achieving molecular remissions. 
Drug profile
Although imatinib has proven to be extremely effective in first-line
treatment of CML, producing hematologic, cytogenetic, and
molecular remissions, resistance to the drug frequently develops.
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therapeutic options are extremely limited, and the onset of imatinib
resistance is usually associated with disease progression and
worsening prognosis. There is therefore a need for new treatment
strategies to be developed to override imatinib resistance in CML. 
Dasatinib is an orally active SRC-ABL inhibitor that is currently in
development for the treatment of imatinib-resistant CML. This
compound has shown potent antileukemic activity in cell lines
expressing imatinib-resistant BCR-ABL isoforms, and striking
remissions and significant prolongation of survival in a series of
xenograft mouse models of imatinib-sensitive and imatinib-
resistant CML. Furthermore, dasatinib has shown promising in vitro
activity against malignant bone marrow cells isolated from patients
with imatinib-resistant CML. The apparent ability of dasatinib to
cross the blood–brain barrier in mice suggests that it might also
prove useful in the treatment of patients with intracranial CML.
Preliminary evidence from the initial phase I dose escalation study
is encouraging, indicating that dasatinib can induce hematologic
and cytogenetic responses in patients with imatinib-resistant CML
in all phases of the disease. However, although dasatinib appears
to be able to override the majority of BCR-ABL mutations that
cause imatinib resistance, it does not inhibit at least one
widespread imatinib-resistant BCR-ABL isoform (T315I) (Shah et al.
2005). Dasatinib appears to be generally well tolerated, regardless
of disease phase, and long-term tolerability data are eagerly
awaited. 
Although dasatinib is still in the initial stages of clinical
development, early evidence suggests that its potential impact on
the treatment of CML could be substantial. Not only could dasatinib
provide a much needed treatment option for patients with imatinib-
resistant CML, but also, combined with imatinib, it might prove to
be useful in delaying the onset of resistance seen with imatinib
monotherapy. Furthermore, dasatinib, in combination with other
agents known to be active in CML, may also prove useful for
purging the residual leukemic cells that persist even in patients
whose disease is controlled by imatinib. 
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